Literature DB >> 468444

Effects of tetrahydrocannabinol on arterial and intraocular hypertension.

W J Crawford, J C Merritt.   

Abstract

Clinical studies were conducted to determine the relationship between simultaneous changes in heart rate, blood pressure, and intraocular pressure in systemic normotensive (N=8) and hypertensive (N=8) open-angle glaucoma patients (N=16) after inhalation of tetrahydrocannabinol (THC). Insignificant changes occurred in arterial and ocular pressures after placebo pertubations. The functional responses after 2.8% THC inhalation in sitting normotensive and hypertensive patients included invariable increases in heart rate (range 20-62 beats/min greater than control) followed by substantial decreases in systolic pressure (range 12-52 mmHg less than control), diastolic pressure (range 6-28 mmHg less than control), and intraocular pressure (range 6-21 mmHg less than control). The intensity and duration (3-4 hours) of the arterial and ocular pressure responses to THC were greater in hypertensives than in normotensive patients. The salient observation after THC inhalation was that the changes in ocular pressure paralleled the changes in blood pressure in each glaucoma patient. These findings suggest that the positive chronotropic response to THC tends to maintain cardiac output which limits further decreases in blood pressure and the capillary filtration of aqueous humor decreases or the reabsorption of aqueous humor increases because of the systemic hypotensive effect attending THC inhalation.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 468444

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  18 in total

Review 1.  Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?

Authors:  Barbara Malinowska; Marta Baranowska-Kuczko; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  Glaucoma blindness in African Americans: have 55 years of therapies, technologies, and talent altered blindness rates?

Authors:  J C Merritt
Journal:  J Natl Med Assoc       Date:  1996-12       Impact factor: 1.798

Review 3.  Glaucoma, hypertension, and marijuana.

Authors:  J C Merritt
Journal:  J Natl Med Assoc       Date:  1982-08       Impact factor: 1.798

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 5.  Cardiovascular pharmacology of cannabinoids.

Authors:  P Pacher; S Bátkai; G Kunos
Journal:  Handb Exp Pharmacol       Date:  2005

Review 6.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.

Authors:  Christopher T Dibble; Eli V Gelfand; Christopher P Cannon
Journal:  Curr Atheroscler Rep       Date:  2007-11       Impact factor: 5.113

Review 8.  Medical marijuana initiatives : are they justified? How successful are they likely to be?

Authors:  Wayne Hall; Louisa Degenhardt
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 9.  Cannabinoid receptors in acute and chronic complications of atherosclerosis.

Authors:  F Mach; F Montecucco; S Steffens
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

10.  Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma.

Authors:  Allan J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.